BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 31494832)

  • 1. Cryoglobulinemic vasculitis with interruption of ibrutinib therapy for chronic lymphocytic leukemia (CLL).
    Wright N; Voshtina E; George G; Singavi A; Field J
    Int J Hematol; 2019 Dec; 110(6):751-755. PubMed ID: 31494832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab.
    Ito Y; Makita S; Maeshima AM; Hatta S; Suzuki T; Yuda S; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Izutsu K
    Intern Med; 2018 Aug; 57(16):2395-2398. PubMed ID: 29526963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe pneumonia associated with ibrutinib monotherapy for CLL and lymphoma.
    Kreiniz N; Bejar J; Polliack A; Tadmor T
    Hematol Oncol; 2018 Feb; 36(1):349-354. PubMed ID: 28156016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
    Ryan CE; Sahaf B; Logan AC; O'Brien S; Byrd JC; Hillmen P; Brown JR; Dyer MJ; Mato AR; Keating MJ; Jaglowski S; Clow F; Rezvani AR; Styles L; Coutre SE; Miklos DB
    Blood; 2016 Dec; 128(25):2899-2908. PubMed ID: 27802969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia.
    Hampel PJ; Call TG; Rabe KG; Ding W; Muchtar E; Kenderian SS; Wang Y; Leis JF; Witzig TE; Koehler AB; Fonder AL; Schwager SM; Van Dyke DL; Braggio E; Slager SL; Kay NE; Parikh SA
    Oncologist; 2020 Nov; 25(11):974-980. PubMed ID: 32886416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome.
    Albi E; Baldoni S; Aureli P; Dorillo E; Del Papa B; Ascani S; Di Ianni M; Falzetti F; Sportoletti P
    Tumori; 2017 Nov; 103(Suppl. 1):e37-e40. PubMed ID: 28708231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Ibrutinib Therapy Reverses CD8
    Parry HM; Mirajkar N; Cutmore N; Zuo J; Long H; Kwok M; Oldrieve C; Hudson C; Stankovic T; Paneesha S; Kelly M; Begum J; McSkeane T; Pratt G; Moss P
    Front Immunol; 2019; 10():2832. PubMed ID: 31921116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
    Woyach JA; Ruppert AS; Heerema NA; Zhao W; Booth AM; Ding W; Bartlett NL; Brander DM; Barr PM; Rogers KA; Parikh SA; Coutre S; Hurria A; Brown JR; Lozanski G; Blachly JS; Ozer HG; Major-Elechi B; Fruth B; Nattam S; Larson RA; Erba H; Litzow M; Owen C; Kuzma C; Abramson JS; Little RF; Smith SE; Stone RM; Mandrekar SJ; Byrd JC
    N Engl J Med; 2018 Dec; 379(26):2517-2528. PubMed ID: 30501481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infection with ibrutinib in patients with chronic lymphocytic leukemia: How strong is the association?
    Ball S; Vutthikraivit W; Maiti A; Short NJ
    Eur J Haematol; 2018 Sep; 101(3):418-420. PubMed ID: 29791043
    [No Abstract]   [Full Text] [Related]  

  • 10. [Improvement of autoimmune cytopenia with ibrutinib in a chronic lymphocytic leukemia patient complicated by monoclonal immunoglobulin deposition disease].
    Nakamura M; Yoshioka S; Yamashita D; Hara S; Ishikawa T
    Rinsho Ketsueki; 2019; 60(10):1449-1454. PubMed ID: 31695006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparable Efficacy of Idelalisib Plus Rituximab and Ibrutinib in Relapsed/refractory Chronic Lymphocytic Leukemia: A Retrospective Case Matched Study of the Polish Adult Leukemia Group (PALG).
    Puła B; Budziszewska BK; Rybka J; Gil L; Subocz E; Długosz-Danecka M; Zawirska D; Waszczuk-Gajda A; Iskierka-Jażdżewska E; Kopacz A; Szymczyk A; Czyż J; Lech-Marańda E; Warzocha K; Jamroziak K
    Anticancer Res; 2018 May; 38(5):3025-3030. PubMed ID: 29715135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia: A systematic review and meta-analysis of randomized trials.
    Zhou Y; Lu H; Yang M; Xu C
    Medicine (Baltimore); 2019 Aug; 98(33):e16915. PubMed ID: 31415440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.
    Stephens DM; Byrd JC
    Blood; 2019 Mar; 133(12):1298-1307. PubMed ID: 30642919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre-ibrutinib era: Incidence and risk factors.
    Georgantopoulos P; Yang H; Norris LB; Bennett CL
    Cancer Med; 2019 May; 8(5):2233-2240. PubMed ID: 30983123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An 81-Year-Old Man with a 6-Year History of Chronic Lymphocytic Leukemia Presenting with Disease Flare Following Ibrutinib Discontinuation.
    Pozzi S; Potenza L; Giusti D; Colaci E; Pioli V; Leonardi G; Maccaferri M; Luppi M; Marasca R
    Am J Case Rep; 2022 Aug; 23():e935941. PubMed ID: 36016481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical safety of ibrutinib in chronic lymphocytic leukemia.
    Molica S
    Expert Opin Drug Saf; 2015 Oct; 14(10):1621-9. PubMed ID: 26359217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
    Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
    Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H
    Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia.
    Morande PE; Sivina M; Uriepero A; Seija N; Berca C; Fresia P; Landoni AI; Di Noia JM; Burger JA; Oppezzo P
    Blood; 2019 May; 133(19):2056-2068. PubMed ID: 30814061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent janus kinase-signaling in chronic lymphocytic leukemia patients on ibrutinib: Results of a phase I trial.
    Spaner DE; McCaw L; Wang G; Tsui H; Shi Y
    Cancer Med; 2019 Apr; 8(4):1540-1550. PubMed ID: 30843659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.